Similarly, a nationwide Danish cohort study reported a lower incidence of prostate cancer in individuals using GLP-1RAs compared to those on basal insulin, particularly in older adults and those with preexisting CV disease [332]. The gene discussed is INS; the disease is prostate carcinoma.